| Returns | 1W : -1.1% , 1M : 4%,1Y : 91.4% |
| Peers & Returns | 1W | 1M | 1Y |
| CADILA HEALTHCARE LTD | -1.1% | 4% | 91.4% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -2.7% | 4.8% | 35.3% |
| DR REDDYS LABORATORIES LTD | -3.9% | 3.4% | 81.9% |
| DIVIS LABORATORIES LTD | -4.7% | -2.1% | 99.6% |
| CIPLA LTD | -3.9% | 4.7% | 73.8% |
| BIOCON LTD | -3% | -0.7% | 65.8% |
| AUROBINDO PHARMA LTD | -3% | 6.9% | 97.4% |
| LUPIN LTD | 1.6% | 13.8% | 47.2% |
| TORRENT PHARMACEUTICALS LTD | -4.9% | -2.7% | 46.9% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
41.16
P/E Calculated based on EPS of 11.49
[ Mar2020 - Consolidated Results ] 4.67
P/B Calculated based on Book Value of 101.33
[ Mar2020 - Consolidated Results ] 3.36
P/S Calculated based on Revenues of 14396.7 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
33% 18% 14% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.33 0.42 0.37 0.37 |
0.77 0.76 0.62 0.72 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Consolidated | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
4.95% 6.33% -9.98% -9.85% |
13.47% 34.48% 336.44% 410.98% |
| QtrlyTrend |
4
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
